文摘
摘要目的:确定阿尔茨海默病(AD)脑脊液(CSF)生物标志物的概要文件在两个原因快速进行性痴呆(RPD):克雅氏病(CJD)和自身免疫性脑炎(AIE)。
背景:库贾氏症是prion-mediated, RPD的致命的原因,而AIE是一种潜在的RPD模拟库贾氏症临床治疗的原因。广告脑脊液生物标志物可能以RPD排除速度比典型的广告但实用程序从AIE歧视库贾氏症不是阐明。
设计/方法:患者27 RPD收到罗氏Elecsys广告脑脊液生物标志物检测在梅奥诊所的一年,包括12个可能的或明确的库贾氏症患者和15 NMDA-R患者,NIF, LGI1, CASPR2, DPPX或IgGLON5 antibody-confirmed(9/15)可能的或明确的AIE。Total-tau (t-tau) phosphorylated-tau (p-tau),并使用逻辑回归amyloid-β-42水平进行比较。
结果:比AIE T-tau是更大的在库贾氏症(置信区间1.19 - -2.12或1.47,p = .0043)。T-tau在高架库贾氏症病例的92%(平均970,范围236 - > 1300 pg / mL),其中50%以上的上限分析测量;而AIE病例的20%(平均235,范围80 - > 1300 pg / mL) t-tau升高,其中都antibody-negative。此外,t-tau / p-tau比率比AIE在库贾氏症(置信区间1.56 - -6.60或2.71,p = .0040)。p-tau / amyloid-β-42比例是相似的在库贾氏症和AIE但低于广告报道;库贾氏症4/12和2/15 AIE p-tau / amyloid-β-42比率升高。年龄、性别、教育和RPD患者的疾病持续时间中位数是可比的。
结论:T-tau和T-tau / p-tau比率比AIE在库贾氏症。t-tau / p-tau比率RPD的区分这些原因。p-tau / amyloid-β-42比例是相似的在库贾氏症和AIE。
披露:常先生没有披露。天已收到博士个人薪酬在5000 - 9999美元的范围为Parabon Nanolabs担任顾问。天已收到博士个人薪酬在500 - 4999美元的范围作为一个编辑,副主编,或编辑顾问委员会成员力学(EBSCO健康)。天已收到博士个人薪酬在10000 - 49999美元的范围为巴罗法作为专家证人。天已收到博士研究机构国立卫生研究院/ NIA的支持。天已收到博士研究的机构支持陈扎克伯格倡议。天已收到博士研究的机构阿尔茨海默氏症协会的支持。天已收到博士研究机构国立卫生研究院/研究所的支持。天已收到博士个人薪酬在500 - 4999美元的范围区域会议上担任主持人(CME)与德克萨斯社会神经。天已收到博士个人薪酬在500 - 4999美元的范围作为格兰特(报酬)和宾夕法尼亚卫生部审查。 Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with American Academy of Neurology. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing Education, Inc. Dr. Day has a non-compensated relationship as a Clinical Director with AntiNMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities. Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. McKeon has received research support from Euroimmun AG. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received research support from Viela Bio. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Prof. Algeciras-Schimnich has nothing to disclose. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Jones has nothing to disclose. Dr. Toledano has nothing to disclose. Dr. Li has nothing to disclose.
